PCMA Report Makes the Case for Specialised Meetings
PCMA Insights has published "2026 PCMA Healthcare & Life Sciences: The Pulse of Global Events". Experience Columbus sponsored the report. It is the second of four sector reports PCMA Insights is publishing with MCI. Convene carried the findings on 8 October 2026 under the byline of Barbara Palmer, the magazine's deputy editor.
The report projects the drug, medical device and life sciences markets at a combined $2.6 trillion by 2030. PCMA reads that projection as good news for demand for healthcare events.
The report's stated direction is a move to "fewer, smaller, higher-quality meetings with clearer ROI". It names tighter budgets, the changing needs of healthcare practitioners and the competition for their attention.
Associations: Specialty Meetings
Large-scale, lecture-heavy congress models are losing effectiveness, according to the report. Clinician engagement with pharmaceutical companies is dropping, and sponsors scrutinise returns.
The report describes clinicians spreading their attention across congresses that carry deeper clinical relevance. The European Society for Medical Oncology holds more than 50,000 members. In 2023 the society held meetings in seven cities alongside its flagship multi-tumor congress. Each of those meetings centred on specific tumor types, therapies and technology, and some drew as few as 400 people.
The report treats the flagship congress and the specialty meeting as two formats an association can run in the same year. It credits specialty meetings with deeper disease-specific education, stronger expert communities and more targeted discussion of treatments and patient subgroups.
Corporate Planners: Smaller, Invitation-Only Events
Average marketing budgets have fallen 21 per cent at pharmaceutical companies, and clinicians are accepting contact from fewer companies, according to the report. Seven out of 10 pharmaceutical leaders call doing more with less their biggest opportunity. The report reads that as a signal that event budgets could shrink.
The report recommends planners move money to smaller hands-on, product-linked workshops, advisory boards, roundtables and other invitation-only formats. Those formats let the planner choose who to invite and track results. The report also recommends keeping in-person sessions focused on high-value interaction and adding hybrid layers to extend the event's reach.
Destinations: Sector Strengths
The report directs destinations and venues to position around healthcare sector strengths. It names local life sciences clusters, research institutions and hospital networks.
Healthcare events convene multiple stakeholders in one room, according to the report. It recommends partnerships with hospitals, universities and associations so that a destination sits inside the ecosystem that produces the event.
CancerCon: A Patient-First Model
CancerCon runs annually under the nonprofit Stupid Cancer. The event is designed for adolescents and young adults diagnosed with cancer.
More than 300 cancer survivors, their caregivers and others gathered at the 2026 event, held last spring in Seattle. Workshops covered mental health, financial hardship, career disruption and isolation.
Healthcare practitioners were part of the CancerCon 2026 mix. The programme carried a breakout track for healthcare and nonprofit professionals and an Education Gallery where they presented posters. A Stupid Cancer press release cited Seattle's leadership in healthcare and its active local cancer survivor community among the reasons for the host city.
The Report Series
PCMA Insights says the series carries market data, an analysis of sector events and recommended strategies plotted to specific sectors and business roles. Four sector reports are due from the publisher with MCI.
The PCMA item carries no registration price, no room block, no named hotel and no attendance forecast for any PCMA event. Its figures cover markets and budgets, and they sit inside the report.